
Keywords: ADCC، سمیت سلولی سمیت وابسته به آنتی بادی; Crohn's disease; IBD; Inflammatory pathways; TNF inhibitors; Ulcerative colitisADA, Adalimumab; ADCC, Antibody-dependent cellular cytotoxicity; CD, Crohn's disease; CDC, Complement-dependent cytotoxicity; CZP, Certolizumab pegol; ETA, Etanercept; FcγR, Fc